Search

everythinglearnresearchcommunity

for

Search:↓

New methods to improve the healing abilities of mesenchymal stem cells for disease treatment are promising but need more research.

Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.

Stem cell activity influences autoimmune disease outcomes by affecting immune responses and tissue regeneration.

Immunoadsorption successfully treated a man's resistant polymyositis.

Systemic immunotherapies are used for immune-related hair loss but not usually for genetic hair loss, unless the patient has both conditions.

Exosomes from certain cells can improve hair regrowth by changing the immune response.

An imbalanced scalp microbiome may worsen alopecia areata severity and inflammation, but treatment can partially restore balance.

Regulatory T cells help heal skin wounds by reducing inflammation and promoting tissue repair.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

JAK inhibitors are effective for treating moderate-to-severe alopecia areata.

Tumor immunotherapy can cause hair loss by disrupting hair follicle immunity.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

Patients with alopecia areata have higher levels of certain immune markers, suggesting new treatment targets.

MDSC-Exo can treat autoimmune alopecia areata and promote hair regrowth in mice.

IL-27 may help prevent hair loss by creating immune-suppressing cells.

Anti-complement agents could effectively treat autoimmune diseases with fewer side effects.

Controlling immune responses with biomaterials can reduce scarring and improve skin regeneration.

CD28 is a promising target for treating alopecia areata with belatacept.

CD28 is a promising target for treating alopecia areata with belatacept.

Belatacept may be a promising treatment for alopecia areata.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.

Hair follicle-derived IL-7 and IL-15 are crucial for maintaining skin-resident memory T cells and could be targeted for treating skin diseases and lymphoma.

Certain immune cells contribute to skin autoimmune diseases, and some treatments can reverse hair loss in these conditions.